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1 Cascades and key points 
1.1 Guideline key points 
• Strongyloides stercoralis is a soil-transmitted helminth, but it has a unique life cycle 
that can be completed in the human host, in a process known as autoinfection. 
• Worldwide, the burden of disease is substantial (300–400 million infections). 
Strongyloidiasis is mainly prevalent in the tropics and subtropics, but there is as yet 
no global public health strategy for controlling the parasite. 
• Infection is particularly serious, and may be disseminated outside the alimentary 
tract, in immunocompromised people—those with human T-cell lymphotropic virus 
type I (HTLV-I) infection and those receiving immunosuppressive drugs. 
• Clinical signs are often absent, but they may be diagnostic (larva currens). Diarrhea 
and malabsorption may be present in chronic infection. 
• The diagnosis was traditionally established by identifying larvae in feces (using the 
Baermann funnel technique), but this has been progressively replaced by 
commercially available serodiagnostic kits. 
• The treatment of choice is single-dose ivermectin 200 µg/kg. An alternative is 
albendazole, but this is significantly less effective and is not recommended. 
• Infection can be prevented by avoiding skin contact with soil that contains larvae. 
1.2 WGO cascades for the diagnosis and management of strongyloidiasis 
1.2.1 About WGO cascades 
WGO cascades: a hierarchical set of diagnostic, therapeutic, and management options for 
dealing with risk and disease, ranked by the resources available. 
World Gastroenterology Organisation (WGO) guidelines and cascades are intended to 
highlight appropriate, context-sensitive, and resource-sensitive management options for 
all geographical areas, regardless of whether they are “developing,” “semi-developed,” or 
“developed.” WGO cascades are context-sensitive, and the context is not necessarily 
defined solely by resource availability. 
Cascade options both for diagnosis and management of strongyloidiasis are key, and 
represent the most important part of this document. Particular emphasis is given to gold 
standard, medium-resource, and low-resource categories. In addition, we also suggest 
one or more algorithms that should guide the clinician through the pathway of the 
patient’s clinical history, clinical signs and symptoms, diagnostic tests, and treatment 
options. 
1.2.2 WGO cascades for the diagnosis of strongyloidiasis 
Table 1 Cascade options for diagnosing strongyloidiasis 
Resource level Cascade of diagnostic options 
Gold standard IgG anti-Strongyloides serology plus one fecal test: Baermann or PCR 
Medium resources IgG anti- Strongyloides serology plus one fecal test: STS 
Low resources One fecal test: STS 
PCR, polymerase chain reaction; STS, spontaneous tube sedimentation. 
N.B.: For confirmation of eradication after treatment, a negative fecal test plus a reduction in the serology titer is 
required. Refinements of PCR diagnosis are still evolving. 
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1.2.3 Cascade for the management of strongyloidiasis 
For the strongyloidiasis treatment cascade, there is only really one option, which is single-
dose ivermectin, irrespective of the local resource level. In case of treatment failure and 
in view of the lack of evidence for alternative treatments, we recommend repeating the 
ivermectin course over 2 days. 
Table 2 Cascade with resource-sensitive options for managing strongyloidiasis 
Resource level Cascade of therapeutic options 
Gold standard Single-dose ivermectin 
Medium resources Single-dose ivermectin 
Low resources Single-dose ivermectin 
 
2 Introduction 
Strongyloidiasis is an infection with Strongyloides stercoralis (Fig. 1), a roundworm that 
occurs widely in tropical and subtropical areas, but also in countries with temperate 
climates (Table 3). 
• Human strongyloidiasis is caused by two species of the parasitic nematode 
Strongyloides. Of these, S. stercoralis is the most common pathogen for humans; 
S. fuelleborni is found sporadically in Africa and Papua New Guinea. 
• Infective S. stercoralis larvae can replicate in the bowel and directly autoinfect 
positive individuals—autoinfection is the major issue that differentiates 
strongyloidiasis from other soil-transmitted helminthiasis (STH) macroparasite 
infection. The main species that infect people are the roundworm (Ascaris 
lumbricoides), the whipworm (Trichuris trichiura), and hookworms (Necator 
americanus and Ancylostoma duodenale) [1]. 
• The adult male worm is found only in the soil. It is not a tissue parasite and is not 
found in the human host. 
• The adult female worm is very small and almost transparent. It measures 
approximately 2.2–2.5 mm in length, with a diameter of 50 µm, and it lives in tunnels 
between the enterocytes in the human small bowel. 
• Infective larvae can replicate in the contaminated soil and infect exposed individuals. 
Strongyloidiasis is different from all other soil-transmitted helminthic infections 
because the eggs produced through parthenogenesis by the parasitic female worm hatch 
when still in the bowel and produce rhabditiform larvae. 
• The larvae are usually excreted in the feces, but some can mature to the filariform 
stage and reinfect the host by penetrating the last part of the bowel or the perianal 
skin (autoinfective cycle). 
• Depending on the host immune response, this can lead to dissemination and 
hyperinfection (Table 4). 
Table 3 World Health Organization (WHO) key facts on strongyloidiasis 
• An estimated 370 million people are infected worldwide [2] (see also section 2.5); precise data 
on prevalence are unknown in countries where it is endemic. 
• Infection is acquired through direct contact with contaminated soil during agricultural, domestic, 
and recreational activities; autoinfection can occur. 
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• Like other soil-transmitted helminthiases, the risk of infection is associated with poor hygiene, 
making children especially vulnerable to infection. 
• Strongyloidiasis is frequently underdiagnosed, because many cases are asymptomatic; 
moreover, commonly used diagnostic methods lack sensitivity. 
• Without appropriate therapy, the infection does not resolve and may persist for life. 
• Infection may be severe and even life-threatening in cases of immunodeficiency. 
• No public health strategies for controlling the disease have been developed at the global level. 




Table 4 S. stercoralis infection types—terminology explained 
Strongyloidiasis pathways of infection 
Autoinfection A mostly asymptomatic process that enables the parasite to survive 
indefinitely in the human host 
Hyperinfection A process of intense autoinfection; the phase in which third-stage larvae can 
be found in fresh stools 
Disseminated 
infection 
The outcome of hyperinfection: larvae can be found anywhere, including in 
the sputum, urine, and gastric juice 
 
WGO Global Guideline Management of strongyloidiasis 7 
© World Gastroenterology Organisation, 2018 
 
Fig. 1 The microscopic appearance of S. stercoralis. a First-stage larva. b Young female. c The 
posterior end of the young female. A, anus; GP, genital primordium; I, intestine; M, mouth; Oe, 
esophagus; V, vulva. Source: Umur et al., Turkish Journal of Veterinary and Animal Sciences 
2017;41:312–5 [3]. 
There are two important stages in the life cycle of the worm, the rhabditiform stage and 
the filariform stage (Figs. 2, 3). 
 
Fig. 2 The rhabditiform larva of S. stercoralis, which may be mistaken for that of the hookworm. 
Source: Pidchayathanakorn (2015), www.slideshare.net [4]. 
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Fig. 3 Strongyloides stercoralis seen in a duodenal biopsy specimen from an adult patient in Zambia. 
Source: Kelly, Medicine 2015;43:253–8 [5] (reproduced with permission from Elsevier, Inc.). 
2.1 Soil-transmitted helminthiases and strongyloidiasis 
Although strongyloidiasis has a similar route of infection to the other soil-transmitted 
helminthiases, it needs additional diagnostic tools beyond microscopy and requires 
different treatment. In areas in which preventive anthelmintic chemotherapy with 
ivermectin has been used to control onchocerciasis or lymphatic filariasis, there has been 
a noticeable reduction in the prevalence of strongyloidiasis [6–10]. The WHO Essential 
Medicines Committee has included ivermectin in its list, including in combination with 
albendazole, for strongyloidiasis. Some 900 million people are now receiving this 
combination as part of neglected tropical disease (NTD) campaigns [11]. 
2.2 Pathophysiology 
Strongyloides stercoralis has a unique and complex life cycle. Figure 4 outlines the unique 
routes of S. stercoralis replication. 
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Fig. 14  The life cycle of Strongyloides stercoralis. Source: Centers for Disease Control and Prevention 
[12]. 
The life cycle of Strongyloides is more complex than that of most nematodes, with its 
alternation between free-living and parasitic cycles and its potential for autoinfection and 
multiplication within the host. There are two types of cycle: 
• The free-living cycle. The rhabditiform larvae passed in the stool can either molt 
twice and become infective filariform larvae (direct development), or molt four times 
and become free-living adult males and females that mate and produce eggs from 
which rhabditiform larvae hatch. The latter in turn can either develop into a new 
generation of free-living adults or into infective filariform larvae. The filariform 
larvae penetrate the human host’s skin to initiate the parasitic cycle. 
 The free-living stage of the nematode’s life cycle is limited to a maximum of one 
generation [13]. This is a unique feature of strongyloidiasis that has important 
implications both for treating infected people and for environmental control in 
preventing transmission. This means that it is vital that eradication therapy must be 
highly effective in order to remove all viable forms of the organism from the infected 
individual. 
• The parasitic cycle. Filariform larvae in contaminated soil penetrate the human skin 
and are transported to the lungs, where they penetrate the alveolar spaces; they are 
carried through the bronchial tree to the pharynx, are swallowed, and then reach the 
small intestine. In the small intestine, they molt twice and become adult female 
worms. The females live threaded in the epithelium of the small intestine and 
through parthenogenesis produce eggs, which yield rhabditiform larvae. The 
rhabditiform larvae can either be passed in the stool (see “free-living cycle” above) 
or can develop further and cause autoinfection. In autoinfection, the rhabditiform 
larvae become infective filariform larvae, which can penetrate either the intestinal 
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mucosa (internal autoinfection) or the skin of the perianal area (external 
autoinfection); in either case, the filariform larvae may follow the previously 
described route, being carried successively to the lungs, the bronchial tree, the 
pharynx, and the small intestine, where they mature into adults; or they may 
disseminate widely in the body. To date, occurrence of autoinfection in humans with 
helminthic infections is recognized only in Strongyloides stercoralis and Capillaria 
philippinensis infections. S. stercoralis is much more common and widespread. In 
strongyloidiasis, autoinfection explains the existence of infections persisting in 
persons who have not been in an endemic area for many years (the current record is 
65 years) and the life-threatening morbidity of hyperinfection in 
immunocompromised individuals—both unusual for worm infections. 
2.3 Disease burden and endemicity 
Strongyloidiasis is endemic in tropical and subtropical regions (Figs. 5–8), and the 
prevalence is probably much higher than the 100 million people previously quoted: 
higher estimates of up to 370 million people have been published [2]. It is also widespread 
in eastern Europe, and scattered foci of the infection have been reported in elderly people 
in the Mediterranean region. 
We know little about the prevalence of infection and less about the clinical burden of 
morbidity. If it is indeed widespread, the risk of iatrogenic hyperinfection (with 
immunosuppressive management) is a challenge. It is thought that strongyloidiasis 
infects up to 40% of the population in some areas of the tropics and subtropics [14]. 
 
Fig. 25 The highest prevalence rates of strongyloidiasis. Source: Puthiyakunnon et al., PLoS 
Neglected Tropical Diseases 2014;8:e3018 [15]. 
Important notes: Australia, like other developed countries, is known to have Strongyloides “hot spots” 
that are not shown on this map (notably some migrants from endemic regions have it, but it is also 
endemic in some Aboriginal populations in the north of Australia) [13,16]). 
The figure illustrates how poor the data are. It is implausible that Strongyloides is absent from most of 
Africa and Asia. Other studies could have been cited that include evidence that Strongyloides infection 
is widespread. It is equally implausible that some countries shown have population-wide prevalences 
higher than 50%; the possibility of selection bias should be considered. 
Migrant infections may occur in any country and may represent a potential global 
hazard. The disease can present in a consulting room anywhere. 
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Fig. 47 Prevalence of strongyloidiasis in Latin America. Source: Buonfrate et al., Epidemiology and 
Infection 2015;143:452–60 [18]. 
 
 
Fig. 58 Prevalence of S. stercoralis in refugees and migrants by country. Source: Schär et al., PLoS 
Neglected Tropical Diseases 2013;7:e2288 [14]. 
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2.4 Risk factors and special groups at risk of infection 
The biggest risk factor overall is socio-economic disadvantage in a relevant environment 
in which Strongyloides is endemic. 
• Poverty, poor housing, poor sanitation; walking barefoot, living in an environment in 
which open defecation occurs 
• Prisoners of war 
• Refugee status—refugees from countries in which strongyloidiasis is endemic 
• Travelers to and from endemic areas 
• Some studies have reported male sex, advanced age, animal–human transmission, 
and humid, wet climates in the tropics and subtropics as risk factors [17] 
2.5 Risk factors and special groups at risk for disseminated infection 
• Immunosuppressive medication—especially corticosteroids, but also tacrolimus and 
chemotherapeutic agents 
• Patients with altered cellular immunity 
• Human T-lymphotropic virus type 1 infection 
• Neoplasms, particularly hematologic malignancies (lymphoma, leukemia) 
• Organ transplantation (kidney allograft recipients) 
• Minor/possible risk factors: collagen vascular disease, malabsorption and 
malnutrition states, end-stage renal disease, diabetes mellitus, local host factors, 
diverticular and blind loops (persistent strongyloidiasis in a blind loop in the 
intestine) 
2.6 Strongyloidiasis and immunosuppressed patients 
Strongyloidiasis ranges from asymptomatic to severe forms and can lead to 
hyperinfection syndrome and disseminated disease, associated with a high 
mortality rate in immunosuppressed patients. 
In the tropics, there are many patients with rheumatoid arthritis, bronchial asthma, and 
glomerulonephritis who receive long-term steroid treatment. Patients can purchase 
steroids directly from pharmacies. 
Strongyloidiasis is not an important AIDS-associated opportunistic infection, but it is 
an opportunistic infection associated with human T-lymphotropic virus type I (HTLV-I) 
[19]. Although patients with human immunodeficiency virus/acquired immune 
deficiency syndrome (HIV/AIDS) can have disseminated strongyloidiasis or 
hyperinfection syndrome, observational studies have not shown an increased risk in this 
population [20]. 
2.7 Mortality and morbidity 
Acute strongyloidiasis is often asymptomatic and can remain hidden for decades. 
Immunocompetent patients often have asymptomatic chronic lifelong infections if 
untreated. 
Chronic infections are a potentially important cause of undisclosed morbidity. There is 
also a lack of efficient diagnostic tools, which are often cumbersome and have low 
sensitivity, so that the true prevalence of infection and morbidity is not known. Since 
strongyloidiasis is viewed as an unusual disease, there has been little investment in 
diagnostic or epidemiological surveys, especially in children. 
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Clinically apparent strongyloidiasis can lead to cutaneous, gastrointestinal, and 
pulmonary symptoms. 
3 Physical signs and symptoms 
The key to diagnosing strongyloidiasis (Table 5) is to have an index of suspicion—the 
diagnosis can only be made for certain when the worm is identified in stool. If there is a 
low worm burden, and due to the intermittent release of larvae in stool, it is often 
impossible to detect the worm if only a single stool is examined. Serial analysis of 
specimens taken over 3 days is necessary. A white blood cell count (WBC) is important, 
as is eosinophilia (high in 50% of patients). 
A patient’s eosinophilia status can be confusing: it is a most helpful sign in simple, 
uncomplicated infections and is mostly absent in disseminated strongyloidiasis. 
Table 5 Uncomplicated strongyloidiasis: physical signs and symptoms 
Disease state Symptoms 
Acute  • Larva currens—intradermal migration of Strongyloides (most 
characteristic sign, but exceedingly rare in this phase) 
• Itch (usually on feet) 
• Wheezing/cough, low-grade fever 
• Epigastric tenderness 
• Diarrhea, nausea/vomiting 
Chronic 
Usually the result of 
autoinfection 
• Larva currens (most characteristic sign; see Fig. 9) 
• Epigastric tenderness 
• Asymptomatic/vague abdominal complaints 
• Intermittent diarrhea (alternating with constipation) 
• Occasional nausea and vomiting 
• Weight loss (if heavier infection) 
• Itching or recurrent skin rashes (chronic urticaria) 
 
 
Fig. 9 An erythematous burrow of larva currens on a patient’s buttock. Note: a biopsy scar from 
4 weeks earlier is visible. Source: Smith et al., Archives of Dermatology 1976;112:1161–3 [21]. 
Table 6 lists signs and symptoms that can be seen with hyperinfection syndrome and 
disseminated strongyloidiasis [20]. 
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Table 6 Signs and symptoms in hyperinfection and disseminated strongyloidiasis 
Gastrointestinal manifestations 
• Abdominal pain, nausea, vomiting, diarrhea 
• Ileus, bowel edema, intestinal obstruction 
• Mucosal ulceration and subsequent peritonitis or bacterial sepsis 
• Massive intestinal hemorrhage 
Pulmonary manifestations and findings 
• Cough, wheezing, dyspnea, hoarseness 
• Pneumonitis 
• Hemoptysis 
• Respiratory failure 
• Diffuse interstitial infiltrates or consolidation on chest radiographs 
Neurologic findings 
• Aseptic or Gram-negative meningitis 
• Larvae have been reported in the CSF, meningeal vessels, dura, and epidural, subdural, and 
subarachnoid spaces 
Systemic features 
• Peripheral edema and ascites secondary to hypoalbuminemia from protein-losing enteropathy 
• Recurrent Gram-negative bacteremia/sepsis from larvae carrying bacteria through mucosal walls 
• Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 
• Peripheral blood eosinophilia is frequently absent 
Cutaneous manifestations 
• Recurrent maculopapular or urticarial rash most commonly found on the buttocks, perineum, 
and thighs due to repeated autoinfection, but can be found anywhere on the skin 
• Larva currens—pathognomonic serpiginous or urticarial rash that advances as rapidly as 10 cm/h 
CSF, cerebrospinal fluid. Source: Centers for Disease Control and Prevention [20]. 
4 Diagnosis and differential diagnosis 
Evidence highlights the need to survey patients with eosinophilia even when a history of 
residence or travel in an endemic area is absent [22]. 
Several diagnostic procedures have been developed over the years, and their use 
depends on local availability and relevant expertise: string tests, duodenal aspirates, 
duodenal biopsy, bronchoalveolar lavage (BAL), immunodiagnostic tests, and repeated 
examination of fresh stool with different methods. 
The global prevalence of Strongyloides stercoralis infection has long been 
underestimated. This is likely due to reliance on direct stool microscopy and the Kato–
Katz technique, which are commonly used in prevalence studies but are inadequate for 
S. stercoralis detection [23]. The commonly used fecal-based methods have particularly 
low sensitivity. Microscopy can be improved by examination of several stool samples, as 
well as concentration techniques [24], but the sensitivity remains low. 
In both low/middle-income and also developed countries, the number of personnel 
who are well trained in the microscopic identification of parasites appears to be 
decreasing. 
• The application of molecular assays, still lagging behind virology or bacteriology, is 
expected to increase in parasitology. 
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• Molecular diagnosis of S. stercoralis infection has yet to demonstrate optimal 
sensitivity. 
• Molecular diagnosis is unlikely to completely replace the other diagnostic 
techniques. 
• Serological assays currently show the highest sensitivity and are important for 
screening of S. stercoralis and assessment of cure [23]. 
Lodh et al. [25] presented research results showing that S. stercoralis DNA can be 
detected in urine. Once available, and if they are sufficiently sensitive, urine sample tests 
may be attractive, as they are much less labor-intensive and resource-intensive and do 
not involve the health risk of examining fresh stool [25]. 
4.1 Stool tests 
Finding the larvae in stool, duodenal fluid, or occasionally in other tissues or fluids by 
means of microscopy establishes a definitive diagnosis of strongyloidiasis (Tables 7, 8; 
Figs. 10, 11). However, because of low larval densities, a single examination is insensitive 
[26]. 
Several methods are used to identify larvae in stool by microscopy: 
• Microscopy after concentration 
— Baermann funnel technique (still regarded as the gold standard) 
— Formalin–ether concentration technique (FECT) 
• Microscopy after culture 
— Harada–Mori filter paper culture 
— Koga agar plate culture 
• Direct microscopy 
— Use of a dissecting microscope to visualize larvae on agar plates 
— Direct smear of feces in saline–Lugol iodine stain 
The use of these methods depends on local resource availability and especially the 
expertise of the microscopist. 
Stool analyses for Strongyloides using the Baermann funnel technique and Koga 
agar culture method are the best fecal diagnostic methods for field settings today. 
These methods detect the parasite with greater sensitivity than other fecal 
methods. 
 
Table 7 Stool tests for strongyloidiasis 
Fecal tests 
Individual diagnosis and 
screening Assessment of cure 
Spontaneous tube 
sedimentation (STS) 
Suitable for basic laboratories in 










technique, Koga agar 
plate culture (APC) 
Up to now the most accurate 
fecal tests, but do not exclude 
infection if negative; 
cumbersome, not routinely 
performed 
Suitable, but will tend to overestimate 
cure rate if used alone 
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Fecal tests 
Individual diagnosis and 
screening Assessment of cure 
Polymerase chain 
reaction (PCR), real-
time PCR (RT-PCR) 
Good, potentially cost-effective, 
allow simultaneous detection of 
multiple pathogens; low 
sensitivity for light infections 
according to some studies 
Many laboratories now have validated 
in-house tests that are routinely used 
(in conjunction with other methods). 
May become reference fecal tests for 
inclusion in trials and cure monitoring 
Source: Buonfrate et al., Clinical Microbiology and Infection 2015;21:543–52 [23]. 
 
• PCR is promising, but not yet standardized; there are concerns about the sensitivity 
of PCR, as it varies across different studies. 
• Anamnart et al. [27] tested stimulation of excretion of S. stercoralis larvae in stool by 
oral administration of a single dose of 400 mg albendazole and suggested that the 
application of albendazole plus the modified formalin–ether concentration technique 
(MFECT) could be used in patients with suspected asymptomatic strongyloidiasis—
including patients with unexplained chronic diarrhea, patients returning from areas 
where strongyloidiasis is endemic, and patients with negative results in other 
parasitological tests [27]. 
 
Table 8 Spontaneous tube sedimentation (STS) protocol 
Procedure steps Description 
Homogenize stools Approx. 10 g of feces is mixed with 10 mL of normal saline solution until 
homogenized (30–60 s or longer, as needed) 
Spontaneous 
sedimentation 
Pour the homogenate into a conical tube (13 × 2.5 cm, 50 mL capacity) 
fitted with a cap using a filter (surgical gauze) at the top of the tube 
Discard gauze and fill the tube with normal saline solution—don’t overfill; 
close cap tightly, taking care to avoid contact with the contents  
Shake for 30 s and leave the tube in the vertical position for 45 min 
Sediment analysis Take the sediment from the bottom of the tube using a plastic pipette 
Place 2–3 drops in two smears; add Lugol’s solution to one of them, cover 
(6 × 2 cm), and observe under a microscope (100 × and 400 ×) 
Source: Tello et al., International Journal of Infectious Diseases 2012;16:e414–6 [28]. 
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Staining and culture techniques (scale bar = 25 µm) 
A Lugol iodine staining of the rhabditiform 
larva in stool. This is the most commonly 
used procedure in clinical microbiology 
laboratories. A single stool examination 
detects larvae in only 30% of cases of 
infection. 
B Human fecal smear stained with auramine 
O, showing orange-yellow fluorescence of 
the rhabditiform larva under ultraviolet light. 
Routine acid-fast staining of sputum, other 
respiratory tract secretions (e.g., bronchial 
washings), and stool may also serve as a 
useful screening procedure. 
C Agar plate culture method. Motile 
rhabditiform or filariform larvae (the latter 
increase the longer the plate is kept) and 
characteristic tracks or furrows, which are 
made by larvae on the agar around the stool 
sample. This method is laborious and time-
consuming (2–3 days), but is more sensitive 
than other procedures (e.g., wet mount 
analysis) in detecting larvae in feces. Tracks 
are marked (arrows and T). S, stool sample 
on agar plate; L, larva or larvae. 
D Gram staining demonstrating S. stercoralis 
filariform larvae (FL). Gram staining of a 
sputum sample is an excellent tool for 
diagnosing pulmonary strongyloidiasis. 
 
Procedure for agar plate cultures 
1 Place stool on agar plate 
2 Seal plate to avoid accidental infection 
3 Store plate for 2 days at room temperature 
4 Larvae crawl over surface and carry bacteria 
with them, creating visible tracks 
5 Examine plates to confirm larvae 
6 Wash with 10% formalin and collect larvae by 
sedimentation  
Repeat this procedure for up to 6 or 7 
consecutive days, because of low parasite load 
and irregular output of larvae in many patients. 
Tests have shown the agar plate method is 
superior to a) direct smear, b) the formalin–
ether sedimentation technique, and c) the filter 
paper method. However, the agar plate method 
is not available globally—sometimes only in 
large towns and teaching hospitals. 
Fig. 610 Diagnostic staining and culture techniques for strongyloidiasis. Source: Siddiqui and Berk, 
Clinical Infectious Diseases 2001;33:1040–7 [29]. 
 
Baermann funnel technique  
The basic Baermann funnel technique, which has many modifications, utilizes a glass funnel with a 
wire mesh basket nested on top. A piece of rubber tubing is slipped over the stem and sealed with 
a clamp. The funnel is filled with water to a level that will cover soil or plant tissue to be placed in 
the basket at the top of the funnel. A piece of tissue paper is used to line the basket and minimize 
the amount of soil that passes through. Nematodes leave the soil or plant tissue, pass through the 
tissue paper liner, and accumulate at the constriction of the tube created by the clamp. After a 
period of time, the clamp is loosened slightly to allow a few milliliters of solution to pass into a 
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container, leaving a fairly clean solution for viewing under a microscope. Laboratories have 
developed variations for every component of this technique. 
Materials  Procedure 
• Paper toweling 
• Fine mesh screen (metal) 
• Small wire basket (or plastic food 
basket) 
• Funnel 
• Tubing (that fits the base at the 
bottom of the funnel) 
• Clamp 
• Microscope, slides, cover slips and 
petroleum jelly (for observing 
specimens) 
• Separate the soil in each sample by passing it through 
the fine mesh screen 
• Once the larger chunks have been broken down, 
spread the sample on a paper tissue. The soil should 
form a layer about 1 cm thick 
• Wrap up the soil within this tissue and place it within 
the wire basket or plastic fruit basket 
• Slip a hose with a clamp onto the neck of a large 
funnel. Position the basket and soil in the funnel—see 
figure below 
 
1 Make sure that the clamp is set on the hose. Fill the 
funnel with enough water so that the bottom of the 
soil is positioned beneath the surface of the water 
2 Leave undisturbed for 2–3 days 
3 You may have to refill the funnel to replace water lost 
to evaporation 
4 During this time, active nematodes will move out of 
the soil and into the water. They will fall to the bottom 
of the funnel and collect in the tube. To retrieve them, 
release the clamp, allowing water to flow through the 
hose into a collection beaker 
Fig. 711 The Baermann funnel technique. 
4.2 Serodiagnosis of strongyloidiasis 
In comparison with the Baermann technique and agar plate culture, serological tests have 
greater sensitivity, although some authors have concerns about their specificity [20]. 
• Many serological tests cross-react with filarial parasites, schistosomes, and Ascaris 
lumbricoides, decreasing the specificity of the tests. 
• It can be difficult to distinguish between active cases and historical cases, as 
antibodies can persist for some time. 
• More specific serological tests using recombinant antigens have been and are 
continuing to be developed and are available at specific laboratories. 
• Serologic tests typically show a significant drop in titer by 6–12 months after parasite 
eradication, so that they can be used to assess cure [20]. 
The most convenient and widely used serological method is the enzyme-linked 
immunosorbent assay (ELISA) to detect serum immunoglobulin G (IgG) against a crude 
extract of filariform larvae. ELISA is labor-intensive and requires a certain level of 
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laboratory infrastructure for performance and interpretation of results, and this has 
hampered its applicability especially in areas where Strongyloides is endemic [26]. 
Moreover, serology has limited value for follow-up after cure in endemic areas, as 
reinfection is possible. 
4.3 Differential diagnosis 
There are many conditions that produce similar symptoms, including causes of acute and 
chronic diarrhea and malabsorption, other causes of eosinophilia, and other causes of 
severe Gram-negative septicemia. The following should be considered in the differential 
diagnosis: 
• Intestinal infections—amebiasis, bacterial colitis, Shigella, Campylobacter, Yersinia, 
Clostridium difficile; see the WGO Global Guideline on Acute Diarrhea, Table 4 [30]. 
• Non-human hookworm infection, producing cutaneous larva migrans—
distinguished from the larva currens caused by S. stercoralis by the absence of 
scabbing, rapid migration, perianal involvement and wide band of urticaria in larva 
currens. 
• Inflammatory bowel disease. 
• Irritable bowel syndrome. 
• Functional abdominal disorders. 
• Drugs—nonsteroidal anti-inflammatory drugs (NSAIDs) and many others—are 
possible causes of eosinophilia. 
The key diagnostic element is to think of strongyloidiasis as a possible diagnosis and 
identify the parasite directly and/or through serologic/molecular tests. 
5 Management of strongyloidiasis 
• Spontaneous cure cannot be expected, due to the parasite’s unique autoinfection life 
cycle. 
• Treat all patients with strongyloidiasis, even when asymptomatic, because of the risk 
of hyperinfection—a potentially fatal complication. 
• Reliable diagnosis of patients at risk is needed for accurate recognition and treatment 
before immunosuppressive therapy is initiated, or in patients with HTLV-I or human 
immunodeficiency virus (HIV) infection. 
• If emergency immunosuppression is required in a patient who may have previously 
undiagnosed strongyloidiasis, and diagnostic tests are not rapidly available (very few 
hospitals can do same-day serology), presumptive treatment with ivermectin should 
be considered. 
• Cure can be achieved with single-dose ivermectin. 
• Failure of treatment with ivermectin is generally due to the impairment of host 
immunity (frequent in patients with HTLV-I infection) [26,31]. 
5.1 Uncomplicated strongyloidiasis 
The treatment of strongyloidiasis (Table 9) is difficult because in contrast to other 
helminth infections, the Strongyloides worm burden has to be eradicated completely. 
• Complete eradication is difficult to ascertain, because of the low worm load and 
irregular larval output. 
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• A definitive cure cannot be established on the basis of a negative follow-up stool 
examination alone—it also requires a decline in both serological titers and 
eosinophilia. 
• A single stool analysis for strongyloidiasis was found to be negative in up to 70% of 
known cases of Strongyloides infection. Reliable testing requires multiple stool 
examinations, probably at least three and with suitable techniques. 
Table 9 Preferred medication for strongyloidiasis 
Ivermectin   
Brand names: 
Stromectol, Mectizan 
• Drug of choice for acute and chronic strongyloidiasis 
• Binds selectively with glutamate-gated chloride ion channels in 
invertebrate nerve and muscle cells, causing cell death 
• Half-life is 16 h; metabolized in liver 
Adult dose  • 200 µg /kg as a single oral dose  
Pediatric dose  • If > 2 years or > 15 kg, administer as in adults 
• If < 15 kg: safety and efficacy not established 
Contraindications  • Documented hypersensitivity 
Interactions  • None reported  
Pregnancy  • Safety for use during pregnancy has not been established 
• Do not use in first trimester of pregnancy and avoid use until after 
delivery, if possible 
• If there is (a risk of) hyperinfection, the benefit outweighs the risk and 
the women should be treated 
Precautions  • Treat mothers who intend to breastfeed only when the risk of delayed 
treatment outweighs possible risks to the newborn caused by 
ivermectin excretion in milk 
• Perform stool examinations to verify eradication of infection 
• Repeat courses of therapy may be required in patients who are 
immunocompromised 
• May cause nausea, vomiting, mild CNS depression, and drowsiness 
• Ivermectin may very rarely precipitate encephalitis in people who have 
concomitant heavy infection with Loa loa, due to the mass killing of 
microfilariae in the CNS. Loiasis should be excluded when treating 
patients who come from endemic areas 
Use as public health 
intervention  
• The use of single-dose ivermectin is currently being considered as a 
treatment in community campaigns in endemic areas, as part of a 
comprehensive preventive chemotherapy strategy 
CNS, central nervous system. Source: Medscape [32]. 
 
• In the tropics, follow-up is a problem and if only fecal testing is available, it becomes 
the method of choice. 
• Albendazole (400 mg b.i.d. for 3 days) is sometimes used as an alternative or 
compromise [33,34]. However, the efficacy of albendazole in the treatment of 
strongyloidiasis has been shown to be very low in comparison with ivermectin, and 
it should therefore not be used unless there is no alternative [35]. 
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5.2 Hyperinfection or disseminated infection 
Although some authors state that these terms describe two different aspects of the 
infection (hyperinfection: high levels of larvae in the usual body parts; dissemination: 
larvae present in any body part, not usually included in the parasitic cycle), they can 
probably be used interchangeably. In fact, they both refer to a very high parasite load and 
rapid spread of the infection—usually in immunosuppressed patients and often 
associated with corticosteroid treatment. Hyperinfection carries a high risk of Gram-
negative septicemia, so broad-spectrum antibiotics are usually given, especially to 
prevent bacterial meningitis. 
In critically ill people with hyperinfection or disseminated strongyloidiasis who are 
unable to take oral medicines, ivermectin has been administered successfully by the 
subcutaneous route [36]. For critically ill people, ivermectin is given daily for a duration 
of at least 14 days, with the total duration of treatment depending on when microscopic 
examination of body fluids positive for larvae become negative (this can be stool or urine, 
or others in cases of hyperinfection) [37]. 
5.3 Prevention and disease control 
Infection is prevented by avoiding direct skin contact with soil containing infective larvae. 
People at risk, especially children, should wear footwear when walking on areas with 
infected soil. Patients at risk should be identified and appropriate diagnostic tests should 
be performed before they begin immunosuppressive therapy. 
Persons in household contact with patients are not at risk for infection. The proper 
disposal of human excreta reduces the prevalence of strongyloidiasis substantially. 
No accepted prophylactic regimen exists and no vaccine is available. 
Standard precautions should be observed for patients hospitalized with 
strongyloidiasis. Wearing gloves and gowns and diligent handwashing hygiene is 
important for those coming into potential contact with the patient’s feces [20]. 
• Early detection and effective treatment of S. stercoralis infection. 
• Screening of patients who are at risk for chronic strongyloidiasis before 
immunosuppressive treatment is started, especially with corticosteroids. 
• Preventive chemotherapy (PC) for S. stercoralis infection is not yet recommended by 
WHO, nor is it included in the strategy for soil-transmitted helminth control. 
However, consistent side benefits on S. stercoralis prevalence have been 
demonstrated after lymphatic filariasis and onchocerciasis elimination programs 
that used repeated PC with ivermectin/albendazole or with ivermectin alone [38]. 
• Proper evaluation of treatment using stool examination (with highly sensitive tests 
such as the Baermann technique, filter-paper culture, and agar-plate culture) and 
specific IgG serology follow-up for 1–2 years [39]. 
• Overseas presumptive treatment programs in refugee populations from countries 
where intestinal parasites are endemic (hookworm, Trichuris trichiura, Ascaris 
lumbricoides, and Strongyloides stercoralis) [40]. 
• The installation and use of safe waste disposal systems still remains important [41]. 
• Wearing footwear could interrupt transmission of strongyloidiasis, but the cultural 
acceptability of footwear is low, particularly in hot climates, so other environmental 
control methods should be assessed [42]. People who don’t have shoes often don’t 
have chairs, and then the buttocks are an additional target. 
• Detect anthelmintic resistance at an early stage. Various in vivo and in vitro methods 
are available for assessing the efficacy of anthelmintics, and specific laboratory 
methods can be applied to confirm a suspicion of resistance in the field—e.g., as 
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described in the World Association for the Advancement of Veterinary Parasitology 
(WAAVP) study recommendations and guidelines [43–45]. 
The study by Forrer et al. [46] showed that community-based single-dose ivermectin 
treatment for S. stercoralis plus sanitation effectively reduced the infection risk in rural 
communities in Cambodia, with over 85% of villagers remaining negative 1 year after 
treatment. Infection control is feasible and highly beneficial, particularly in combination 
with improved sanitation [46]. 
Khieu et al. [47] found that individuals with a latrine at home were infected with S. 
stercoralis significantly less frequently than those without one. The calculated population 
attributable risk would be reduced by 39% if all participants used a latrine for defecation 
[17,47]. 
Croker and She noted that the high prevalence of eosinophilia among persons with 
latent Strongyloides infection in Los Angeles County highlights the importance of 
screening individuals with eosinophilia in whom more common causes have been ruled 
out [48]. 
The StrongNet [38], an international network for improving diagnosis and access to 
treatment for strongyloidiasis control, advocates better and field-friendly diagnosis as 
well as the availability of ivermectin on a large scale for the control of strongyloidiasis in 
endemic areas. Following the efforts of this network, ivermectin has recently been 
included to the WHO’s Essential Medicines List for the treatment of strongyloidiasis; the 
ultimate goal is to develop a public health control strategy and to include S. stercoralis in 
the WHO’s preventive chemotherapy strategy for soil-transmitted helminthiasis . 
5.4 Prognosis 
Acute and chronic strongyloidiasis have a good prognosis. However, untreated infection 
can persist for the remainder of the patient’s life, due to the autoinfection cycle. A patient’s 
prolonged absence from an endemic area is no guarantee of freedom from infection. 
Severe disseminated infection is commonly a fatal event, and it is often unresponsive to 
therapy. 
In chronic strongyloidiasis, immunosuppression poses a risk for accelerated 
autoinfection. This may result in a sepsis-like syndrome, S. stercoralis hyperinfection, and 
the dissemination of larvae to distant organs such as the central nervous system, causing 
S. stercoralis–associated meningitis [49]. 
6 Appendix 
6.1 Abbreviations 
Table 10 Abbreviations used in this guideline 
AIDS acquired immune deficiency syndrome 
APC agar plate culture 
BAL bronchoalveolar lavage 
CNS central nervous system 
CSF cerebrospinal fluid 
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ELISA enzyme-linked immunosorbent essay 
FECT formalin–ether concentration technique 
HIV human immunodeficiency virus 
HTLV-I human T-lymphotropic virus type I 
MFECT modified formalin–ether concentration technique 
NSAID nonsteroidal anti-inflammatory drug 
NTD neglected tropical disease 
PC preventive (anthelmintic) chemotherapy 1 
PCR polymerase chain reaction 
RT-PCR real-time polymerase chain reaction 
SIADH syndrome of inappropriate secretion of antidiuretic hormone 
STH soil-transmitted helminthiasis 2  
STS spontaneous tube sedimentation 
WAAVP World Association for the Advancement of Veterinary Parasitology  
WBC white blood cell (count) 
WGO World Gastroenterology Organisation 
WHO World Health Organization 
1. World Health Assembly resolution of 2013 on NTDs (WHA 66.12) definition: Preventive 
chemotherapy means large-scale preventive treatment against helminthiases and trachoma with safe, 
single-dose, quality-assured medicines [50]. 
2. The main species that infect people are the roundworm (Ascaris lumbricoides), the whipworm 
(Trichuris trichiura), and hookworms (Necator americanus and Ancylostoma duodenale) [1]. 
6.2 Gold standard guideline 
• Centers for Disease Control and Prevention. Parasites — Strongyloides. Resources 
for health professionals [Internet]. Atlanta, GA: Centers for Disease Control and 
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